Calendrier des promotions Candel Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.Paramètres de base
IPO date
2021-07-27
ISIN
US1374041093
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 1064.07 | 1 |
P/BV | 4.15 | 4 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -74.53 | 0 |
ROE | -139.56 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.2586 | 10 |
Debt/Ratio | 0.1261 | 10 |
Debt/Equity | 0.6112 | 9 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -75.2 | 0 |
Rentabilité Ebitda, % | 512.91 | 10 |
Rentabilité EPS, % | 47.01 | 6 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 5.13 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 5.46 $ | 0 $ | 0 $ | -6.04 % | 0 % | 0 % |
common.calendar.number_days.30d | 5.43 $ | 5.13 $ | 6.04 $ | -5.52 % | 0 % | 0 % |
common.calendar.number_days.90d | 4.97 $ | 4.39 $ | 6.04 $ | 3.22 % | 0 % | 0 % |
common.calendar.number_days.180d | 8.66 $ | 4.39 $ | 12.21 $ | -40.76 % | 0 % | 0 % |
common.calendar.number_days.1y | 6.27 $ | 3.8 $ | 12.21 $ | -18.18 % | 0 % | 0 % |
common.calendar.number_days.3y | 3.4 $ | 0.675 $ | 14 $ | 50.88 % | 0 % | 0 % |
common.calendar.number_days.5y | 0.675 $ | 0.675 $ | 14 $ | 760 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.675 $ | 0.675 $ | 14 $ | 760 % | 0 % | 0 % |
common.calendar.number_days.ytd | 7.81 $ | 4.39 $ | 12.21 $ | -34.31 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 335.27k | 1968 (57 années) |
Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 506.76k | 1978 (47 années) |
Ms. Ileen B. Winick | Chief People Officer | N/A | |
Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | N/A | 1961 (64 année) |
Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer | N/A | 1969 (56 années) |
Mr. Charles Schoch | Interim CFO, Principal Accounting Officer, Treasurer & Secretary | N/A | 1985 (40 années) |
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, CEO & Director | 1961 (64 année) |
Informations sur l'entreprise
Adresse: United States, Needham. MA, 117 Kendrick Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.candeltx.com
Site web: https://www.candeltx.com